Drug Landscape ›
Narcotic pain medication ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 18
Most-reported reactions
Chest Pain — 2 reports (11.11%) Decreased Appetite — 2 reports (11.11%) Drug Ineffective — 2 reports (11.11%) Lymph Gland Infection — 2 reports (11.11%) Migraine — 2 reports (11.11%) Pain — 2 reports (11.11%) Pulmonary Embolism — 2 reports (11.11%) Sinusitis — 2 reports (11.11%) Abdominal Pain Upper — 1 report (5.56%) Alopecia — 1 report (5.56%)
Source database →
Narcotic pain medication in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Narcotic pain medication approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Narcotic pain medication in United States?
Henry Ford Health System is the originator. The local marketing authorisation holder may differ — check the official source linked above.